benzbromarone has been researched along with Chronic Disease in 13 studies
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout." | 9.08 | Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. ( Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E, 1998) |
| "Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)." | 8.90 | Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "To study the efficacy of allopurinol and benzbromarone to reduce serum urate concentrations in patients with primary chronic gout." | 5.08 | Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. ( Alonso-Ruiz, A; Calabozo, M; García-Erauskin, G; Herrero-Beites, A; Perez-Ruiz, F; Ruiz-Lucea, E, 1998) |
| "Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)." | 4.90 | Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "We considered all randomised controlled trials (RCTs) or quasi-randomised controlled trials (controlled clinical trials (CCTs)) that compared uricosuric medications (benzbromarone, probenecid or sulphinpyrazone) alone or in combination with another therapy (placebo or other active uric acid-lowering medication, or non-pharmacological treatment) in adults with chronic gout for inclusion." | 4.90 | Uricosuric medications for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "In 18 patients with monosodium urate (MSU) crystal proven gout, and after the initiation of successful serum uric acid (SUA)-lowering treatment, an arthrocentesis of the asymptomatic signal joint (11 knees, 7 first metatarsophalangeal joints) was performed every 3 months to obtain a synovial fluid (SF) sample." | 3.74 | Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. ( Pascual, E; Sivera, F, 2007) |
| " The drug is particularly useful in patients with chronic gouty arthritis and tophi, either refractory or allergic to probenecid, sulfinpyrazone, or allopurinol." | 3.65 | Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. ( Yu, TF, 1976) |
| "Gout is a common disorder with clinical signs and symptoms resulting from inflammatory responses to monosodium urate crystals deposited in tissues from extracellular fluids saturated for urate." | 2.50 | Long-term management of gout: nonpharmacologic and pharmacologic therapies. ( Becker, MA; Chaichian, Y; Chohan, S, 2014) |
| "Monitoring blood uric acid (UA) is important in all patients on urate-lowering therapy so that the selection of the effective drugs and dosage adjustments could be made until the target level is reached." | 1.42 | Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy. ( Huang, Y; Zhao, J, 2015) |
| "First choice treatment of acute gout consists of NSAIDs." | 1.31 | [Summary of the Dutch College of General Practitioners' "Gout" Standard]. ( Gorter, KJ; Romeijnders, AC, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Cicero, AFG | 1 |
| Fogacci, F | 1 |
| Kuwabara, M | 1 |
| Borghi, C | 1 |
| Gallos, G | 1 |
| Remy, KE | 1 |
| Danielsson, J | 1 |
| Funayama, H | 1 |
| Fu, XW | 1 |
| Chang, HY | 1 |
| Yim, P | 1 |
| Xu, D | 1 |
| Emala, CW | 1 |
| Chaichian, Y | 1 |
| Chohan, S | 1 |
| Becker, MA | 1 |
| Seth, R | 2 |
| Kydd, AS | 2 |
| Buchbinder, R | 2 |
| Bombardier, C | 2 |
| Edwards, CJ | 2 |
| Zhao, J | 1 |
| Huang, Y | 1 |
| Boxberger, F | 1 |
| Harsch, IA | 1 |
| Brueckl, WM | 1 |
| Hautmann, M | 1 |
| Baum, U | 1 |
| Hahn, EG | 1 |
| Wein, A | 1 |
| Wong, ML | 1 |
| Pascual, E | 1 |
| Sivera, F | 1 |
| Paul, V | 1 |
| Lange, A | 1 |
| Perez-Ruiz, F | 1 |
| Alonso-Ruiz, A | 1 |
| Calabozo, M | 1 |
| Herrero-Beites, A | 1 |
| García-Erauskin, G | 1 |
| Ruiz-Lucea, E | 1 |
| Romeijnders, AC | 1 |
| Gorter, KJ | 1 |
| Yu, TF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for benzbromarone and Chronic Disease
| Article | Year |
|---|---|
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Topics: Acetamides; Allopurinol; Benzbromarone; Chronic Disease; Evidence-Based Medicine; Febuxostat; Gout S | 2021 |
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Febuxostat; Feeding Behavior; Gout; Gout Suppressants; | 2014 |
Allopurinol for chronic gout.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans | 2014 |
Uricosuric medications for chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Controlled Clinical Trials as Topic; Femal | 2014 |
2 trials available for benzbromarone and Chronic Disease
| Article | Year |
|---|---|
[Benzarone for leg edema caused by chronic venous insufficiency].
Topics: Benzbromarone; Benzofurans; Chronic Disease; Clinical Trials as Topic; Edema; Female; Fibrinolytic A | 1983 |
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Drug Administration Schedule; Gout; Gout S | 1998 |
7 other studies available for benzbromarone and Chronic Disease
| Article | Year |
|---|---|
Functional expression of the TMEM16 family of calcium-activated chloride channels in airway smooth muscle.
Topics: Animals; Anoctamin-1; Anoctamins; Asthma; Benzbromarone; Bronchi; Chloride Channels; Chronic Disease | 2013 |
Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy.
Topics: Arthritis, Gouty; Benzbromarone; Biomarkers; Chronic Disease; Feasibility Studies; Humans; Hyperuric | 2015 |
[Chronic gout. Case report of a severe course of disease].
Topics: Adult; Allopurinol; Benzbromarone; Chronic Disease; Drug Therapy, Combination; Gout; Gout Suppressan | 2003 |
Optimal management of chronic gout: attempting to render the (t)issues crystal-clear.
Topics: Allopurinol; Anti-Inflammatory Agents; Benzbromarone; Chronic Disease; Colchicine; Drug Hypersensiti | 2005 |
Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.
Topics: Adult; Aged; Benzbromarone; Chronic Disease; Crystallization; Follow-Up Studies; Gout; Gout Suppress | 2007 |
[Summary of the Dutch College of General Practitioners' "Gout" Standard].
Topics: Acute Disease; Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbr | 2002 |
Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
Topics: Adult; Aged; Arthritis; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Chronic Disease; | 1976 |